Signed a research agreement with the University of Utah for joint development of corneal model
02
Signed an MOU with AIGEN Sciences to implement a new drug development model that incorporates AIGEN’s AI technolog
2024
11
Series C : Yuanta Investment Korea Co., Ltd. / KB-Solidus Investment / KDB Bank / E&Investment / SBI Investment Korea Co., Ltd. / Live Cell Instrument / CEO of the DB, Nam Ho Kim
10
Launch of NanoCalibur™ Lab and filing of patent application
10
Patent granted for LNP manufacturing technology encapsulating mRNAs and ASOs
06
Established Mepsgenus Inc. Silicon Valley Office
04
Designated as Military Manpower Administration’s Office
02
Patent granted for ProMEPS™
01
Patent granted for MST-MPA126
2023
11
Launch of ProMEPS™ (MEPS-AMS, a fully automated robotic system for MPS modeling)
11
Award from the Minister of Trade, Industry, and Energy (MOTIE), ‘Innovative and Fast-Growing Bio Company'
11
Confirmed non-clinical efficacy of MG-GHC24 (Nanomedicine for Glioblastoma) in patient tissues
07
Signing of a Joint Research Agreement about brain tumors (GBM) with ChaBio Hospital
07
Signing of a Cooperative Agreement about evaluation and validation of the Microphysiological System with K-BIO Health
05
Signing of an Agreement to develop extracellular matrix biomaterials with Cellartgen
05
Signing of MOU for Research Services with CRO companies; Corestem Chemon and Woojung Bio
05
MG-PE3’s Patent Registration(Korea)
04
MG-PP3 and MG-GTX13’s Patent Applications
01
Signing of a Collaborative Research Agreement with Georgia Tech, USA
2022
12
Initiating nanoparticle manufacturing and mass production business
07
Series B : KDB Bank / DONG-A SOCIO HOLDINGS / KOLON Investment / KIWOOM Securities Co., Ltd. / CEO of the DB, Nam Ho Kim
06
LNP mass production technology patent application (Microfluidic technology)
06
MG-G101 patent application
03
MEPS-TBC cryopreservation patent grant
2021
11
MG-PE3 PCT application
09
MEPS-TBC, Manufactured & Released
08
Series A (Bridge) : Korea Investment Partners Co., Ltd / SBI Investment Korea Co., Ltd. / KNOTUS Co., Ltd. / Tiumbio Co., Ltd
04
MG-PE3 patent granted in Republic of Korea
03
Started CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease - 1st Drug efficacy
02
Kicked off MEPS-BBB research service using new drug candidates with pharmaceutical companies
01
Expansion & relocation of the office, R&D center, and production facility (Hanyang Tower, 12, Beobwon-ro-11-gil, Songpa-gu, Seoul, Rep. of Korea)
2020
12
Finished PK/PD CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease
